Relevant bibliographies by topics / Tumors

Academic literature on the topic 'Tumors'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumors"

1

GROSU, Luminiţa-Bianca, and Camelia DIACONU. "Cardiac Tumors." Annals of the Academy of Romanian Scientists Series of Medicine 3, no. 1 (2022): 7–12. http://dx.doi.org/10.56082/annalsarscimed.2022.1.7.

Full text
Abstract:
Cardiac tumors represent a rare and challenging clinical situation. They can be primary (benign or malignant) or secondary (metastatic). Secondary tumors are more frequent than the primary tumors. Most of the primary cardiac tumors are benign and originate from the endocardium or myocardium, while the metastatic tumors develop from lung, breast, kidney carcinoma, melanoma and lymphoma. The diagnosis of cardiac tumors is often difficult because of their rarity, variety and nonspecific symptoms. The clinical manifestations depend on tumor’s size, location, infiltration and consist of four categories: systemic manifestations, cardiac manifestations, embolic events, and metastatic manifestations. Echocardiography represents the main imaging technique used to detect cardiac masses. Computed tomography (CT) and magnetic resonance imaging (MRI) are used to achieve more information about tumor’s composition, extension, vascularization, and possibility of surgical treatment. The histological evaluation is necessary for a positive diagnosis and staging of the cardiac tumor. The treatment of cardiac tumors depends on the type of tumor and symptomatology.
APA, Harvard, Vancouver, ISO, and other styles
2

Mathew, George, and Shwetha Jose. "PRIMARY TUMORS AND TUMOR-LIKE LESIONS OF BONE IN CHILDREN." International Journal of Integrative Medical Sciences 4, no. 6 (November 3, 2017): 507–11. http://dx.doi.org/10.16965/ijims.2017.112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Salam, Kazi Shameemus, Samia Quadir, Md Momin Uddin, Syed Farhan Ali Razib, Md Abdus Sattar, Md Mosleh Uddin, and Belayat Hossain Siddiquee. "Surgical Outcome of Parapharyngeal Tumour." Bangladesh Journal of Otorhinolaryngology 27, no. 1 (April 28, 2021): 66–72. http://dx.doi.org/10.3329/bjo.v27i1.53209.

Full text
Abstract:
Background: Parapharyngeal tumours are rare accounting for 0.5-1.5% of all head neck tumuors. The anatomy of the Parapharyngeal space (PPS) is responsible for a wide variety of tumours arising from PPS. Objective: Evaluation of the strategy for parapharyngeal tumor surgery based on preoperative symptoms, clinical signs, imaging investigations and histopathology. Methodology: This retrospective study was carried out in the Department of Otolaryngology and Head Neck surgery in Bangabandhu Sheikh Mujib Medical University (BSMMU) included 32 patients were underwent surgery for primary parapharyngeal tumors between January 2018 and December 2019. Informed written consent was obtained from the patients prior to their inclusion in the study. In regard to histologic type there were 21 cases salivary gland origin tumors and 11 of neurogenic tumors. The following data were evaluated preoperative symptoms, histological type, surgical approach and complications patients were evaluated following a laboratory investigations. Results: The most common symptoms of these tumors were a neck swelling. Total of 18 tumors were located in the prestyloid and poststyloid space cases were located 10(31.25%) and 4(12.50%) in the pre and poststyloid. Majority 12(37.50%) was found pleomorphic adenomaof deep lobe of parotid gland followed by 6(18.75%) were schwannoma,4(12.50%) were neurofibroma, 3(9.38%) were ectopic salivary gland tumor,2(6.25%) were mucoepidermoid carcinoma, 2(6.25%) were adenocarcinoma. First bite syndrome and lower lip palsy were common post operative complications. Transcervical approach was the most often performed approach in this study (56.25%). Conclusion: Parapharyngeal tumours most often derived from parotid gland. Most of them are non-malignant. Pleomorphic adenoma is the more common. Surgical resection being the main stay of treatment. Tumours of this complex anatomy call for careful preoperative planning and great skill for selecting the right approach and for management with minimal morbidity and recurrence. Bangladesh J Otorhinolaryngol; April 2021; 27(1): 66-72
APA, Harvard, Vancouver, ISO, and other styles
4

Welsh, Cynthia. "Glial Tumors." AJSP: Reviews and Reports 25, no. 2 (March 2020): 57–62. http://dx.doi.org/10.1097/pcr.0000000000000364.

Full text
Abstract:
Abstract Glial tumors comprise the majority of primary intra-axial intracranial tumors. Since its introduction in 2016, the revised fourth edition of the World Health Organization (WHO) classification of central nervous system tumors has changed the diagnostic and therapeutic approach in glial tumors (WHO Classification of Tumours of the Central Nervous System [revised fourth edition]; Lyon, France: IARC; 2016). Diffuse gliomas (WHO grades II–IV) are now molecularly stratified based on isocitrate dehydrogenase 1 or 2 mutation status and classified according to 1p/19q codeletion status into astrocytic or oligodendroglial type. Updates now occur faster than new editions of the WHO classification can be prepared, so updates are being issued by way of journal articles from a Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (Brain Pathol 2019;29(4):469–472).
APA, Harvard, Vancouver, ISO, and other styles
5

Olaya, Joffre E., Ravi Raghavan, Laura Totaro, and Alexander Zouros. "Pineal anlage tumor in a 5-month-old boy." Journal of Neurosurgery: Pediatrics 5, no. 6 (June 2010): 636–40. http://dx.doi.org/10.3171/2010.2.peds09294.

Full text
Abstract:
Pineal tumors are rare neoplasms that are categorized into pineoblastomas, pineocytomas, and pineal parenchymal tumors of intermediate differentiation. Pineal anlage tumors are primary pineal tumors with neuroepithelial and ectomesenchymal differentiation and without endodermal differentiation. The authors review the literature and report the case of a 5-month-old boy with a pineal anlage tumor. This is only the sixth case of a pineal anlage tumor reported in the English-language literature adding to the understanding of this tumor's presentation, immunomorphological and molecular characteristics, embryological origin, radiological appearance, treatment outcome, and prognosis.
APA, Harvard, Vancouver, ISO, and other styles
6

Vladova, Paulina, and Sergey Iliev. "Appendiceal neuroendocrine tumors - recent insights." International Journal of Surgery and Medicine 4, no. 3 (2018): 1. http://dx.doi.org/10.5455/ijsm.appendiceal-neuroendocrine-tumors.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sharma, Manupriya, Anjali Soni, and Rashmi Kaul. "Histopathological pattern of ovarian neoplasms in Sub-Himalayan belt of rural India: a four-year study from a tertiary care teaching hospital." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 6, no. 12 (November 23, 2017): 5448. http://dx.doi.org/10.18203/2320-1770.ijrcog20175258.

Full text
Abstract:
Background: Ovarian tumors are one of the ubiquitous and common forms of neoplasms in women. The aim of the study was to understand the pattern of benign and malignant ovarian neoplasms and their distribution in different age groups in rural population of India.Methods: A retrospective study conducted in the Department of Pathology in close collaboration with Department of Obstetrics and Gynecology, Dr. Rajendra Prasad Government Medical College, Kangra at Tanda (HP), India. All the patients irrespective of age group who were operated for ovarian neoplasms (benign or malignant) were included in this retrospective analysis over duration of four years (2013 to 2016). “WHO classification system” was used, for classification of all these ovarian tumors. The incidence of these tumors with respect to age group was also studied.Results: During the study period (2013-2016), there were a total of 242 surgeries for ovarian neoplasms. Of these, majority of the tumours were benign 184 (76%), but an alarming number of women had malignant ovarian tumours 51 (21%), remaining 7 (3%) cases were borderline. Age wise distribution was 7% (16/242) in less than 20 years age, 19% (46/242) in 20-30 years age, 29% (69/242) in 30-40 years age group, 24% (59/242) in 40-50 years and remaining 21% (52/242) in more than 50 years age group. Pre-dominantly benign tumors were surface epithelial tumors (serous/ mucinous cystadenoma), germ cell tumors (mature cystic teratoma) and endometrioma. Major malignant tumors were surface epithelial tumors (serous/mucinous cystadeno-carcinoma), and germ cell tumors (dysgerminoma, immature teratoma).Conclusions: In this sub-Himalayan belt of rural India, the incidence of benign ovarian tumors was 76%. Borderline ovarian tumors were seen in 3% cases and the remaining 21% cases were malignant ones. Even though benign tumors were the commonest for each age group, however as the age of women increased the proportion of malignant tumors in them increased. Surface epithelial tumors are the most common class of tumors in both benign and malignant tumors. Serous cystadenoma is the most common ovarian tumor overall as well as most common benign tumor whereas serous cystadeno-carcinoma is most common malignancy. Stromal ovarian tumor (one case) is a rarity. Only one woman had bilateral ovarian tumor.
APA, Harvard, Vancouver, ISO, and other styles
8

Pathania, Anup Singh. "Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges." Cancers 16, no. 12 (June 12, 2024): 2201. http://dx.doi.org/10.3390/cancers16122201.

Full text
Abstract:
The tumor immune microenvironment is pivotal in cancer initiation, advancement, and regulation. Its molecular and cellular composition is critical throughout the disease, as it can influence the balance between suppressive and cytotoxic immune responses within the tumor’s vicinity. Studies on the tumor immune microenvironment have enriched our understanding of the intricate interplay between tumors and their immunological surroundings in various human cancers. These studies illuminate the role of significant components of the immune microenvironment, which have not been extensively explored in pediatric tumors before and may influence the responsiveness or resistance to therapeutic agents. Our deepening understanding of the pediatric tumor immune microenvironment is helping to overcome challenges related to the effectiveness of existing therapeutic strategies, including immunotherapies. Although in the early stages, targeted therapies that modulate the tumor immune microenvironment of pediatric solid tumors hold promise for improved outcomes. Focusing on various aspects of tumor immune biology in pediatric patients presents a therapeutic opportunity that could improve treatment outcomes. This review offers a comprehensive examination of recent literature concerning profiling the immune microenvironment in various pediatric tumors. It seeks to condense research findings on characterizing the immune microenvironment in pediatric tumors and its impact on tumor development, metastasis, and response to therapeutic modalities. It covers the immune microenvironment’s role in tumor development, interactions with tumor cells, and its impact on the tumor’s response to immunotherapy. The review also discusses challenges targeting the immune microenvironment for pediatric cancer therapies.
APA, Harvard, Vancouver, ISO, and other styles
9

Joaquim, Andrei Fernandes, Enrico Ghizoni, Marcelo Gomes Cordeiro Valadares, Simone Appenzeller, Simone dos Santos Aguiar, and Helder Tedeschi. "Spinal tumors in children." Revista da Associação Médica Brasileira 63, no. 5 (May 2017): 459–65. http://dx.doi.org/10.1590/1806-9282.63.05.459.

Full text
Abstract:
Summary Introduction: Spinal tumors are rare in the pediatric population, presenting many specific peculiarities when compared to adults. We have performed a broad narrative review to describe the most common spinal tumors in children, discussing their main characteristics and management options. Method: The authors have performed an extensive review of the peer-reviewed literature addressing the aforementioned objectives. Results: Multimodality radiological studies (plain films, 3D computed tomography scan and magnetic resonance imaging) are necessary for proper evaluation and differential diagnosis of spinal tumors in children. In selected cases nuclear medicine imaging is used to improve the chances of a more accurate diagnosis. As a general rule, a fine needle biopsy is recommended after radiological evaluation to confirm the tumor's histology. Primary bone tumors can be divided into benign bone tumors, mostly represented by vertebral hemangiomas, osteoid osteomas, osteoblastomas, aneurismal bone cysts, and eosinophilic granulomas, and malign or aggressive tumors, such as Ewing's or osteogenic sarcomas. Secondary bone tumors (spinal metastases) comprise different tumor histologies, and treatment is mainly based on tumor's radiosensitivity. The characteristics and treatment options of the main spinal tumors are discussed in details. Conclusion: Spinal tumors in children are rare lesions that demand a thorough understanding of their main characteristics for their proper management. Understanding the nuances of spinal tumors in children is of paramount importance for improving outcomes and chances of cure.
APA, Harvard, Vancouver, ISO, and other styles
10

Graham, Donald V., Donatella Tampieri, and Jean-Guy Villemure. "Intramedullary Dermoid Tumor Diagnosed with the Assistance of Magnetic Resonance Imaging." Neurosurgery 23, no. 6 (December 1, 1988): 765–67. http://dx.doi.org/10.1227/00006123-198812000-00016.

Full text
Abstract:
Abstract Intramedullary dermoid tumors are unusual. Traditional methods of diagnosing spinal tumors have included clinical suspicion, plain roentgenography, myelography, and computed tomography. A case of intramedullary tumor provisionally diagnosed preoperatively by traditional methods and specifically as dermoid tumore with the assistance of magnetic resonance imaging is presented. Diagnosis and treatment of spinal dermoid tumors with an emphasis on magnetic resonance imaging is discussed.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumors"

1

Monzón, Gonzales Janneth Silvana. "Tumores del intestino delgado: Perfil Clínico-Patológico, Enero 2003 a Marzo 2005, Hospital Edgardo Rebagliati Martins." Bachelor's thesis, Universidad Ricardo Palma, 2006. http://cybertesis.urp.edu.pe/handle/urp/199.

Full text
Abstract:
El objetivo principal de este trabajo es definir las características clínicas de los tumores de intestino delgado según su tipo. Se revisaron retrospectivamente los archivos de anatomía patológica y los archivos de historias clínicas del Hospital Edgardo Rebagliati Martins, eligiendo los casos con diagnóstico de tumores benignos y malignos del intestino delgado, correspondientes al período de enero de 2003 a marzo de 2005. De ellos se seleccionó un total de 107 casos que cumplían con los criterios de inclusión y se estudió su historial clínico para llenar la ficha de recolección de datos. De la observación de los 107 casos seleccionados surge como categoría relevante el predominio del tumor de tipo histológico maligno, siendo el más frecuente el adenocarcinoma (68,9%), seguido del linfoma (21,60%). Entre los tumores benignos el más recurrente resulta ser el pólipo del duodeno (46,15%). La edad promedio de aparición de la enfermedad fue a partir de la sexta década de vida y, en cuanto a las manifestaciones clínicas, el dolor abdominal fue el predominante en todos los tipos de tumor encontrados. Con este trabajo demostramos que la disminución de peso corporal y el dolor abdominal son manifestaciones importantes para el diagnóstico. Frente a todo paciente de 60 años o más con disminución de peso, recurrente dolor abdominal y sin otra molestia aparente debe pensarse en tumor de intestino delgado.
APA, Harvard, Vancouver, ISO, and other styles
2

Swanson, Kristin Rae. "Mathematical modeling of the growth and control of tumors /." Thesis, Connect to this title online; UW restricted, 1999. http://hdl.handle.net/1773/6764.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cuny, Thomas. "New regulatory mechanisms in the growth of endocrine tumors : digestive neuroendocrine tumors, pitiutary adenomas." Thesis, Aix-Marseille, 2016. http://www.theses.fr/2016AIXM5061.

Full text
Abstract:
Bien que rares, les tumeurs endocrines développées chez l'Homme demeurent problèmatiques. Une meilleure compréhension des mécanismes qui régulent leur croissance constitue un objectif essentiel pour identifier des cibles thérapeutiques nouvelles.Dans la première partie de cette thèse, nous avons étudié l'impact du microenvironnement tumoral (MeT), définit par l'ensemble des facteurs qui encerclent la niche tumorale primitive, sur la croissance des tumeurs endocrines digestives. In vitro, nous observons un effet prolifératif réciproque entre des fibroblastes, l'une des cellules pivots du MeT, et des lignées cellulaires humaines de tumeurs endocrines pancréatiques, tel qu'il est susceptible d'exister in situ. Dans une seconde partie, nous avons montré que le pegvisomant, un antagoniste du récepteur de l'hormone de croissance utilisé chez des patients atteint d'adénome hypophysaire somatotrope, n'a pas d'effet prolifératif in vitro sur les cellules somatotropes adénomateuses
Although rare, endocrine tumors developed in Humans remain problematic, such as a better understanding of their regulatory mechanisms of growth represent a step forward to identify new therapeutical targets.In the first part of this thesis, we investigated the impact of the tumor microenvironment (TME), as defined by the factors surrounding the tumor primitive niche, on the growth of human digestive endocrine tumors. We, here, showed the occurrence of a reciprocal proliferation between human fibroblasts, a key cell within the TME, and human pancreatic neuroendocrine tumor cell lines, suggesting that human fibroblasts may constitue a new therapeutical target of interest in the TME of digestive endocrine tumors. In a second part, we showed that pegvisomant (PEG), a growth hormone receptor antagonist currently used in patients with GH-secreting pituitary adenoma, did not impact in vitro the proliferation rate of GH-secreting adenoma cells and therefore is suitable in patients with a persisting GH-secreting pituitary adenoma residue after surgery
APA, Harvard, Vancouver, ISO, and other styles
4

Tai, Kai-chun Dora, and 戴啟真. "Krukenberg tumours of colorectal origin: experience of a tertiary referral centre and review of theliterature." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B4562043X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nakayama, Tomitaka. "MDM2 gene amplification in bone and soft-tissue tumors : association with tumor progression in differentiated adiposetissue tumors." Kyoto University, 1997. http://hdl.handle.net/2433/202202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cataldo, A. "ANTI-TUMOR ACTIVITY OF CPG-ODN IN OVARIAN XENOGRAFT TUMORS." Doctoral thesis, Università degli Studi di Milano, 2014. http://hdl.handle.net/2434/229558.

Full text
Abstract:
Synthetic oligodeoxynucleotides expressing CpG motifs (CpG-ODN), Toll-like receptor 9 (TLR9) agonists, are able to induce innate/adaptive immune responses and can enhance the antitumor activity of DNA-damaging chemotherapy and radiation therapy in preclinical mouse models. It was recently reported that peritumoral CpG-ODN treatment in preclinical models of ovarian cancer, activating TLR-9 expressing cells in tumor microenvironment, induces modulation of DNA repair genes and sensitizes cancer cells to DNA-damaging Cisplatin treatment. In this thesis we investigated whether this treatment induces modulation of miRNAs in tumor cells and their relevance to chemotherapy response. Array analysis identified 20 differentially expressed miRNAs (16 down- and 4 up-regulated) in human IGROV-1 ovarian tumor cells from CpG-ODN-treated mice versus controls. Evaluation of the role of the 3 most differentially expressed miRNAs on sensitivity to Cisplatin of IGROV-1 cells revealed significant increased Cisplatin cytotoxicity upon ectopic expression of hsa-miR-302b (up-modulated in our array), but no increased effect upon reduced expression of hsa-miR-424 or hsa-miR-340 (down-modulated in our array). The impact of expression levels of all 20 differentially expressed miRNAs were associated with time to replase and overall survival probability in two data sets of ovarian cancer patients treated with platinum. It was found that hsa-miR-302b expression was significantly associated with time to relapse or overall survival in these patients. Use of bio-informatics tools identified 19 mRNAs potentially targeted by hsa-miR-302b, including HDAC4 gene, which has been reported to mediate Cisplatin sensitivity in ovarian cancer. Both HDAC4 mRNA and protein levels were significantly reduced in IGROV-1 cells overexpressing hsa-miR-302b. Altogether, these findings indicate that hsa-miR-302b acts as a ‘‘chemosensitizer’’ in human ovarian carcinoma cells and may represent a biomarker able to predict response to Cisplatin treatment. Moreover, the identification of miRNAs that improve sensitivity to chemotherapy provides the experimental underpinning for their possible future clinical use. In the second part of this thesis we tested the efficacy of CpG-ODN in combination with other possible therapeutic agents in ovarian carcinoma ascites-bearing athymic mice, to mimic clinical treatment situations in advanced human ovarian disease. Mice injected i.p. with IGROV-1 ovarian cancer cells were treated at different stages of ascites progression for 4 weeks with CpG-ODN alone or in combination with Bevacizumab, Polyinosinic:Polycytidylic acid (Poly(I):Poly(C)), Gefitinib, Cetuximab and Cisplatin. In mice treated when ascitic fluid began to accumulate, CpG-ODN combined with Bevacizumab, Poly(I): Poly(C) or Gefitinib did not significantly increase Median Survival Times (MST), as compared with that using CpG-ODN alone, whereas MST in mice treated with CpG-ODN plus Cetuximab was significantly increased (>103 days for combination vs 62 days for CpG alone; P = 0.0008), with 4/8 mice alive at the end of the experiment. In mice showing evident and established ascites, evaluated with increase of abdominal volume and body weight (27.9 ± 0.8 g after vs 23 ± 1.1 g before tumor cell injection), treatment with Cisplatin in addition to CpG-ODN/Cetuximab led to significantly increased MST (105.5 days; P = 0.001), with all mice still alive at 85 days, over that using CpG ODN/Cetuximab (66 days), Cetuximab/Cisplatin (18.5 days), Cisplatin (23 days) or saline (16 days). At a very advanced stage of disease (body weight: 31.4 ± 0.9 g), when more than half of control mice had to be sacrificed 6 days after starting treatments, the triple-combination therapy still increased MST (45 days; P = 0.0089) vs controls. These data indicated that CpG-ODN combination therapies that enhance the immune response in the tumor microenvironment and concomitantly target tumor cells are highly efficacious even in experimental advanced malignancies. Although differences in the distribution of TLR9 in mice and humans and the enrichment of this receptor on innate immune cells of athymic mice must be considered, our results indicate a promising strategy to treat ovarian cancer patients with bulky ascites.
APA, Harvard, Vancouver, ISO, and other styles
7

Marcu, Loredana Gabriela. "Deterministic modelling of kinetics and radiobiology of radiation-cisplatin interaction in the treatment of head and neck cancers." Title page, contents and abstract only, 2004. http://hdl.handle.net/2440/37961.

Full text
Abstract:
One of the main objectives of combining radiation treatment and chemotherapy is to obtain a therapeutic gain by an improved tumour control with less or no enhancement of normal tissue toxicity. The optimal schedule for the combined treatment of cisplatin-radiation is still under investigation. Neither the optimal time interval, nor the most adequate sequence of administration of cisplatin and radiation are known. The results of the trials are also inconclusive. Some trials showed a supra-additive effect from the administration of cisplatin before radiotherapy, others, on contrary, from the injection of drug after radiotherapy. The present work encompasses the major challenges brought by the combined modality treatment: cisplatin-radiotherapy. The major goal of this work was to investigate the optimal treatment sequencing between cisplatin and radiotherapy and also the optimal schedule for head and neck carcinomas. Therefore, a computer-based tumour model with literature-given biological parameters has been developed which has allowed the simulation of treatment with radiation and chemotherapy. Radiotherapy has been simulated on the virtual tumour and the effects of radiotherapy on tumour regression and regrowth have been analyzed. Also, the mechanisms of cisplatin's action on tumour have been implemented, and the phenomena of drug resistance and tumour repopulation during chemotherapy studied. Finally, the combined modality treatment has been simulated, and the effect of drug-radiation interaction on tumour behaviour evaluated. The current investigation has shown that cisplatin administered immediately before radiation gives similar tumour control to the post-radiation sequencing of the drug. Furthermore, the killing effect of the combined modality treatment on tumour increases with the increase in cell recruitment. The individual cell kill produced by cisplatin and radiation leads to an additive-only tumour response when the treatments are given concurrently, and for a synergistic effect cisplatin must potentiate the effect of radiation. The final conclusion, by which cisplatin administered on a daily basis leads to a better tumour control than cisplatin administered weekly, is in accordance with the latest trial results on head and neck cancers. Therefore, treatment regimens that correlate better with the pharmacokinetics and the radiobiological properties of the therapeutic agents result in better outcomes.
Thesis (Ph.D.)--School of Chemistry and Physics, 2004.
APA, Harvard, Vancouver, ISO, and other styles
8

Lu, Dan. "Tumor priming enhances particle delivery to and transport in solid tumors." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1144936804.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Martinez, Mata Guillermo. "Mixomas odontogenicos : analise clinicopatologica e imunohistoquimica de 67 casos." [s.n.], 2005. http://repositorio.unicamp.br/jspui/handle/REPOSIP/288397.

Full text
Abstract:
Orientador: Oslei Paes de Almeida
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba
Made available in DSpace on 2018-08-05T09:05:53Z (GMT). No. of bitstreams: 1 MartinezMata_Guillermo_M.pdf: 1070617 bytes, checksum: 13db66187a1a59eeaa5b18ca3a02cb9d (MD5) Previous issue date: 2005
Resumo: O objetivo deste trabalho foi analisar as características clínicas, radiográficas, histopatológicas e perfil imunohistoquímico de 67 casos de mixomas odontogênicos (MOs), assim como relatar uma das casuísticas mais extensas da literatura mundial. Nesta pesquisa, o gênero feminino foi o mais afetado com 48 casos (71,64%) enquanto o gênero masculino foi em 19 (28,36%) (relação homem/mulher 1:2,5). A idade dos pacientes variou de 10 a 84 anos, média de 32,7. O sitio mais afetado foi a mandíbula em 27 casos (40.29%) Clinicamente, os MOs apresentaram-se como lesões assintomáticas em 29 (43,28%) casos, em 9 (13,43%) houve dor leve a moderada enquanto em outros 9 (13,43%) houve aumento de volume com evolução lenta. Radiograficamente dos 47 casos com dados disponíveis, 29 (43,28%) casos foram descritos como lesões radiolúcidas e 18 (26,86%) como mistas/multiloculares com aparência de favos de mel ou bolhas de sabão. Microscopicamente MOs apresentaram abundantes células fusiformes e estreladas homogêneas dispersas em um estroma mixóide e frouxo sem apresentar mitoses ou pleomorfismo celular. Em 6 casos (8,95%) evidenciaram presença de epitélio e 16 (23,88%) apresentaram calcificações do tipo distrófica. A reatividade de mastócitos foi positiva pela imunohistoquímica (clone AA1) em 27 casos (40,29%) e na coloração de azul de toluidina em 19 (28,35%). Treze dos 67 casos apresentaram epitélio imunoreativo para o coquetel de citoqueratinas AE1/AE3 e CK 14. Apenas 2 dos 13 casos foram positivos para CK 19 sugerindo uma possível origem odontogênica. As células fusiformes e estreladas foram reativas para vimentina em 67 casos, para a-actina músculo liso específica em 27 casos (40,29%) e para desmina em 6 (8,95%). Todos os casos foram negativos para a proteína S-100 e CK 8. O anticorpo CD-34 foi positivo em 20 (29,85%) casos, evidenciando múltiplas estruturas vasculares de diversos tamanhos. O marcador de proliferação celular Ki-67 foi positivo em apenas 2 casos apesar de sua alta taxa de recorrência. Baseado nestes achados, podemos sugerir que provavelmente os MOs sejam derivados de elementos mesenquimais, possivelmente de células fibroblásticas modificadas com características de miofibroblastos , e que outras nomenclaturas seriam mais adequadas para denominar esta lesão, tais como mixomas da região maxilar ou mixomas dos ossos gnáticos
Abstract: The aim of this study was to analyze the immunohistochemical profile and clinical, radiographical and histopathological characteristics of 67 cases of odontogenic myxoma (OM), as well as to report the greatest series related in the world literature. Females were more affected with 48 cases (71,64%) whereas males were in 19 (26.83%), male-female ratio 1:2.5. The patient¿s age ranged from 10 to 84 years (mean 32,7 years). The most frequent site affected was mandible with 27 cases (40,29%). Clinically, 29 cases (43,28%) of OM were asymptomatic, 9 cases (13,43%) presented pain and another 9 (13.43%) showed swelling. Radiographically, we disposed of clinical information in 47 cases, of which 29 (43,28%) cases were radioluced lesions and 18 (26,86%) were described as mixed/multilobular lesions of honey/comb or soap/bubble appearance. Microscopically, OM was constituted by a myxomatous background with spindle-shaped and stellate cells. Mitoses and pleomorphism were absent. Epithelium was present in 6 (8,95%) cases and 16 (23.88%) presented dystrophic calcifications. Immunohistochemical analyses revealed that 27 cases (40.29%) were positives for mast cell (clone AA1) and 19 (28,35%) positives for toluidine blue. Thirteen cases (19,47%) were positives for the antibody PAN CK AE1/AE3 and CK 14 respectively. Only 2 cases (2,98%) were positives for CK 19 suggering an possible odontogenic origin. The spindle-shaped and stellate cells showed positivity for vimentin in 67 cases, 27 cases (40,29%) for a-smooth muscle actin positives and 6 (8,95%) for desmin. All 67 cases were S-100 and CK 8 negatives. Twenty cases (29,85%) were immunopositives for CD-34, demonstring multiples blood vessels. Expression of the marker of cellular proliferation Ki-67 was low, being present only in two cases. Based on these findings, we can suggest that OM probably derives from mesenchymal elements, possibly modified fibroblasts with miofibroblastic diferentation, and that others nomenclatures as mixoma of the jaws could be suggest for this lesion
Mestrado
Patologia
Mestre em Estomatopatologia
APA, Harvard, Vancouver, ISO, and other styles
10

Furtado, LuÃs Edmundo Teixeira de Arruda. "IdentificaÃÃo de glicoproteÃnas em membrana de tumores primÃrios do sistema nervoso central utilizando lectinas vegetais acopladas a fluoresceÃna." Universidade Federal do CearÃ, 2010. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=4868.

Full text
Abstract:
FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgico
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior
Lectinas sÃo proteÃnas que pertencem a um grupo heterogÃneo de molÃculas com capacidade de ligaÃÃo especÃfica e reversÃvel a carboidratos. Desde sua descoberta, as lectinas se tornaram importantes ferramentas para a investigaÃÃo de fenÃmenos como a adesÃo, a migraÃÃo e a proliferaÃÃo celular, em condiÃÃes normais e patolÃgicas. Durante o processo de diferenciaÃÃo, cÃlulas tumorais apresentam vÃrios graus de modificaÃÃo na expressÃo de glicoproteÃnas de membrana. Neste aspecto, a investigaÃÃo da estrutura da membrana tumoral pode ser compreendida como um mÃtodo sensÃvel e especÃfico de diagnÃstico. Portanto, o reconhecimento de marcadores capazes de identificar e quantificar estas caracterÃsticas, pode ser usado como ferramenta de diagnÃstico. Neste trabalho propomos um modelo experimental para detectar marcadores de membrana de tumores primÃrios do Sistema Nervoso Central usando lectinas vegetais (Con A e Con Br) acopladas à cromÃforos. Amostras de tumores foram obtidas de pacientes que tinham diagnÃstico clÃnico e radiolÃgico de tumores do Sistema Nervoso Central, apÃs cirurgias realizadas no ServiÃo de Neurologia da Santa Casa de MisericÃrdia de Sobral. As amostras foram processadas e investigadas com tÃcnicas imunohistoquÃmicas, usando lectinas vegetais acopladas à fluoresceÃna, e microscopia de fluorescÃncia. Os resultados mostraram que meningiomas e gliomas apresentaram um padrÃo diferente de interaÃÃo com Con Br-FITC e Con A-FITC quando comparados ao controle (BSA/FITC). Estes dados sugerem que as lectinas vegetais estudadas podem ser ferramentas Ãteis na identificaÃÃo de marcadores de membrana em tumores primÃrios do Sistema Nervoso Central.
Lectins are proteins that belong to a heterogeneous group of molecules capable of binding specifically and reversibly to carbohydrates. Since its discovery, lectins have become important tools for investigating phenomena such as adhesion, migration and cell proliferation in normal and pathological conditions. In the process of differentiation, tumor cells display different degrees of modification in the expression of membrane glycoproteins. In this respect, the investigation of membrane structure tumor can be understood as a sensitive and specific method of diagnosis. Therefore, the recognition of markers capable of identifying and quantifying these characteristics can be used as diagnostic tool. In this paper we propose an experimental model to detect markers of the membrane of primary tumors of the central nervous system using plant lectins (Con A and Con Br) attached to the chromophores. Tumor samples were obtained from patients who had clinical and radiological diagnosis of tumors of the central nervous system after surgeries performed at the Department of Neurology, Santa Casa de Misericordia de Sobral. The samples were processed and investigated with immunohistochemical techniques, using plant lectins coupled to fluorescein, and fluorescence microscopy. The results showed that meningiomas and gliomas showed a different pattern for interaction with Con Br-FITC and Con A-FITC compared to control (BSA / FITC). These data suggest that the studied plant lectins can be useful tools in identifying membrane markers in primary tumors of the central nervous system.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumors"

1

Jeanmart, Louis, ed. Tumors. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-49303-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

1929-, Jeanmart L., and Baleriaux D, eds. Tumors. Berlin: Springer-Verlag, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Santini-Araujo, Eduardo, Ricardo K. Kalil, Franco Bertoni, and Yong-Koo Park, eds. Tumors and Tumor-Like Lesions of Bone. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28315-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Santini-Araujo, Eduardo, Ricardo K. Kalil, Franco Bertoni, and Yong-Koo Park, eds. Tumors and Tumor-Like Lesions of Bone. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-6578-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Davies, A. Mark, Murali Sundaram, and Steven L. J. James, eds. Imaging of Bone Tumors and Tumor-Like Lesions. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-77984-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Picci, Piero, Marco Manfrini, Davide Maria Donati, Marco Gambarotti, Alberto Righi, Daniel Vanel, and Angelo Paolo Dei Tos, eds. Diagnosis of Musculoskeletal Tumors and Tumor-like Conditions. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-29676-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Franchi, Alessandro, ed. Pathology of Sinonasal Tumors and Tumor-Like Lesions. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-29848-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

S, Patchefsky Arthur, and Mountain Clifton F. 1924-, eds. Tumors and tumor-like lesions of the lung. Philadelphia: W.B. Saunders Co., 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vanhoenacker, Filip M., and Mohamed Fethi Ladeb, eds. Imaging of Synovial Tumors and Tumor-like Conditions. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-33635-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ali-Osman, Francis, ed. Brain Tumors. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1385/1592598439.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Tumors"

1

Fatterpekar, Girish M., and Pia C. Sundgren. "Cerebral Neoplasms." In IDKD Springer Series, 41–48. Cham: Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-50675-8_4.

Full text
Abstract:
AbstractIn the past, before 2016, brain tumors were classified into several types, and their respective grades based largely on histology. While this allowed for categorization of tumors, the grading did not always correlate with overall survival. At the same time, neuro-oncology research work demonstrated that tumoral molecular genetics allowed for a better correlation with overall survival. This led to the Revised 2016 WHO classification of brain tumors, which for the first time in neuro-pathology saw the incorporation of mutation profiles applied to classification of brain tumors. Continued development in the field of neuro-oncology meant better categorization of previously described tumors, and the description of newer tumors. This led to another update, the 2021 classification of brain tumors. This chapter provides an overview of these revised brain tumor classification systems, and discusses the imaging profiles of certain select yet important tumor types in detail.
APA, Harvard, Vancouver, ISO, and other styles
2

Fischer, Manfred, and Matthias Schmidt. "Radioiodine-Labeled Meta-Iodobenzylguanidine for Imaging and Treatment of Pheochromocytoma/Paraganglioma and Neuroblastoma." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, 289–303. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_29.

Full text
Abstract:
AbstractFollowing the new WHO classification of tumors of the endocrine organs (Lloyd RV, Osamura RY, Klöppel G, Rodai J, editors. WHO classification of tumours of endocrine organs. Lyon: International Agency for Research on Cancer; 2017), this chapter deals with the development of radionuclide therapy of malignant pheochromocytomas, parangliomas, and neuroblastomas. All of these tumors are expressing the noradrenaline transporter, which is responsible for the active uptake of 131I-meta-iodobenzyguanidine (131I-mIBG) into the tumor cells. This tracer was introduced for diagnostic procedures of the adrenal medulla, for the treatment of adrenal medullary hyperplasia and also for malignant neuroendocrine tumors in 1980/1981, and these treatment indications are still valid until today. For treatment of malignant pheochromocytomas and paragangliomas, an improvement of 5-year overall survival in about 36% was published.In Germany, the most common indication for 131I-mIBG therapy in high-risk neuroblastoma patients is the treatment of persistent mIBG-avid disease before autologous stem cell transplantation. However, 131I-mIBG may also be used in case of neuroblastoma relapse or in palliative intent, in other countries also as first-line treatment. Mean objective tumor response for 131I-mIBG in neuroblastoma was reported with about 32%.Some promising results of recent studies using new tracers (DOTATOC, DOTATATE) with newer beta-emitters are also discussed.
APA, Harvard, Vancouver, ISO, and other styles
3

Triulzi, Fabio Maria. "Embryonal Tumors. Pineal Tumors." In Neuroradiology of Brain Tumors, 139–61. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-38153-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Önerci, T. Metin. "Tumors." In Diagnosis in Otorhinolaryngology, 112–19. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00499-5_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Viegas, Steven F. "Tumors." In Hand Surgery Study Guide, 53–62. New York, NY: Springer New York, 1997. http://dx.doi.org/10.1007/978-1-4612-1910-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Deramond, Hervé, Claude Depriester, Jacques Chiras, Anne Cotten, Nathalie Boutry, and Bernard Cortet. "Tumors." In Percutaneous Vertebroplasty, 125–53. New York, NY: Springer New York, 2002. http://dx.doi.org/10.1007/978-1-4757-3694-6_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pritchard, Douglas J. "Tumors." In Surgery of the Hip Joint, 31–59. New York, NY: Springer New York, 1987. http://dx.doi.org/10.1007/978-1-4613-8628-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Suchomel, P., V. Benes, and M. Kaiser. "Tumors." In Reconstruction of Upper Cervical Spine and Craniovertebral Junction, 247–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-13158-5_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Garrido-Ruiz, Guadalupe, Antoino Luna-Alcalá, and Joan C. Vilanova. "Tumors." In Learning Musculoskeletal Imaging, 23–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-88000-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Raimondi, Anthony J. "Tumors." In Pediatric Neurosurgery, 181–353. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-58827-3_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumors"

1

Iqbal, S. A., H. Shukla, V. Jain, S. Giri, R. Sekhon, and S. Rawal. "Synchronous primary ovarian sex cord tumor and endometrial cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685384.

Full text
Abstract:
Synchronous primary tumors of female genital tract are rare with a rate of about 0.7-1.8% of all gynaecological tumours. Most common primary tumours presenting as synchronous lesions are ovary and endometrium. However, sex cord stromal tumors are rare variety of primary ovarian tumor and synchronous with endometrium is even much rarer. These tumors are detected usually in younger, overweight, nulliparous and perimenopausal female. Synchronous primary tumors of endometrium and ovary have a better prognosis than the either of above alone because these are usually low grade and diagnosed at early stage. We present a report of four cases of synchronous endometrial and sex cord stromal tumors of ovary.
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of CA 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685299.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
3

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of cancer antigen 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685315.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA 19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, were included in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors. Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were nonmucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
4

Manuchehrabadi, N., A. Attaluri, H. Cai, R. Edziah, E. Lalanne, C. Bieberich, R. Ma, A. M. Johnson, and L. Zhu. "Visualization and Quantification of Gold Nanorods Distribution in Prostatic Tumors Using MicroCT Imaging." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80317.

Full text
Abstract:
One uncertainty in use of gold nanorods for laser photothermal therapy is the non-uniform spreading of gold nanorods in tissue after either systemic delivery or intratumoral injections. High concentration of gold nanorods in certain areas influences the resulted optical absorption of the laser and thermal damage to tumors. This also provides challenges in designing optimal heating protocols via modeling thermal transport in laser photothermal therapy. For successful cancer treatment, the tissue should be heated with minimum thermal dosage to induce tumor cell damage, while minimizing overheating in the surrounding healthy tissues. Thus, one of the main challenges for reliable cancer therapy is to precisely control loading and distribution of gold nanorods in the tumour tissue. The critical mass transport processes are the distribution of gold nanorods after injection to the tumor and the redistribution of gold nanorods during laser treatment. Since tumors are opaque, nanostructure distribution in tissue is often studied either by theoretical modeling approaches1, or via dye enhanced imaging on superficial layers of tumors.2 It is important to find a technique which can directly visualize and analyze three-dimensional nanostructure distribution of tumors. Three-dimensional reconstructions of tumors with the ability to trace gold nanorod spreading have the potential for precise theoretical simulation of temperature fields. Previous studies showed that computer tomography (CT) scan is a promising technique to be utilized to characterize the distribution of intratumorally injected magnetic nanoparticles in tumors 3.
APA, Harvard, Vancouver, ISO, and other styles
5

Mukhopadhyay, Asima, Nicola Curtin, and Richard Edmondson. "Evaluation of different methods to assess homologous recombination status and sensitivity to PARP inhibitors in ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685289.

Full text
Abstract:
Methods: Matched samples of ascites and tumor tissue were taken from patients undergoing surgery for epithelial ovarian cancer. Tumor samples were formalin fixed and paraffin embedded (FFPE); ascites samples were used to generate primary cultures (PC). HR status was determined in PCs as previously described.[1] IC50 for the PARP inhibitor Rucaparib was estimated using SRB assays. DNA was extracted from the FFPE tissue. The following techniques were evaluated in PCs or paired FFPE samples: DR-GFP reporter assay, PARP activity assay, BRCA1 expression on immunohistochemistry, BRCA1 methylation status and BRCA1/2 mutation analysis. A next generation sequencing based assay was used to detect mutations and other genomic alterations in a large panel of cancer-associated genes, including BRCA1/2. Results: Paired samples were collected from 64 patients and characterized for HR function. 47/64 (76%) were high grade serous. 44% (28/64)) were HR defective (HRD) by Rad51 assay and correlated with Rucaparib sensitivity (PPV-92%, NPV-100%). Molecular analysis revealed that all mutations and other genomic alterations detected in ascites derived PCs were also found in matched FFPE tumor tissues. All tumors with serous histology contained p53 mutations, whilst the remaining tumors without p53 mutations were non-serous in histology. DR-GFP assay was unreliable in PC due to poor transfection. In a subset of 50 cancers there was reduced BRCA1 expression in the HRD vs. HRC tumours (34.8% vs. 22.7%, ns) whilst in a further subset of 30 cases there was no difference in endogenous or stimulated PARP activity between HRD and HRC tumours. Deleterious BRCA2 mutations were identified in 7 tumors, 6 of which were HRD. Only 1 deleterious BRCA1 mutation was detected but methylation of BRCA1 was identified in 13 of 64 (20%) tumors, 7 of which were HRD. Mutation of BRCA2 was mutually exclusive to methylation of BRCA1. HRD vs. HRC tumours showed BRCA1 methylation (25% vs. 17%) and BRCA1/2 mutation (21% vs. 0.3%). 14/28 (50%) HR defective tumors do not have BRCA1/2 mutations or BRCA1 methylation, suggesting other mechanisms can also result in a HR defective phenotype. 28/64 (43%) of samples demonstrated the HR defective phenotype. In all cases HR status correlated with sensitivity to Rucaparib. Conclusion: As expected, deleterious BRCA2 mutations conferred a HRD phenotype in cells but methylation of BRCA1 was not universally associated with HRD. This may be as a result of only partial silencing of the gene by methylation and further work is required to identify thresholds of methylation which may predict HR status. The use of BRCA1/2 mutation testing alone is unlikely to identify the majority of HR defective ovarian tumors. Assessment of functional status of HRD is the preferred option and further technologies should be developed to simplify the Rad51 assay.
APA, Harvard, Vancouver, ISO, and other styles
6

Chopra, Seema. "Sclerosing sex cord stromal tumour of the ovary: A rare variant of ovarian neoplasms in childhood and adolescence." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685321.

Full text
Abstract:
Case Report: 19 yr old unmarried girl c/o abdominal distension, loss of appetite and Irregular menstrual cycles x 5 months. USG: gross ascites, liver, Lobulated isoechoic mass in right adnexa, 7x5 cm, abutting right ovary. CA125: 1297 U/ml. FNAC Degenerated crushed cells & stromal fragments. Few scattered benign oval/spindle cells. Laparoscopy f/b laparotomy: 6 litres of straw colored asciic fluid drained. Uterus, left adnexa normal. Rt ovarian mass 6x7 cm, bilobed, arising from ovary. Solid, stuck in POD Adherent to gut. Right oophrectomy done. CA-125: 22 u/ml on day 6 post op. HPE – Sclerosing stromal tumor. Discussion: Sclerosing sex cord stromal tumour of the ovary is a rare tumor; accounts for 6% of ovarian stromal tumors Over a 100 reported tumors in literature. 80% of SST seen in second and third decade of life. Essentially a benign tumour, Usually a unilateral nonfunctioning tumor. Few cases with elevated serum CA-125 and hormonal abnormalities have been reported. Endocrine alterations caused by secretion of estrogen, progesterone or testosterone; induction of precocious puberty. Conclusion: Unilateral oophrectomy is the treatment. No recurrence of the tumor in the patients treated by oophorectomy or by conservative resection of the tumor. Excision of the tumor isfollowed by normal menses, pregnancy has also been reported.
APA, Harvard, Vancouver, ISO, and other styles
7

Svaasand, Lars D., and Charles J. Gomer. "Optical and thermal properties of ocular tumors." In OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1988. http://dx.doi.org/10.1364/oam.1988.thy1.

Full text
Abstract:
Laser-induced hyperthermic treatment of ocular tumors represents a promising clinical modality which could be used either alone or in conjunction with ionizing radiation or chemotherapy. The presentation emphasizes a discussion of the relevant optical and thermal properties of ocular media and tumors. Experimental results from murine tumor model studies of the optical and thermal properties of tumors, such as retinoblastomas and malignant melanomas, are given. The optical penetration depth (attenuation to 1/e = 0.37) of heavily pigmented tumors such as melanotic melanomas is <0.5 mm in the visible part of the spectrum, whereas the penetration depth in the near IR is more than four times larger. The penetration depth of retinoblastomas is, however, significantly larger. The optical penetration depth for this tumor ranges from 1.6 mm in the 488–515-nm region and up to ~7.5 mm at 1064-nm wavelength. The temperature distribution is monitored during laser irradiation, and the experimental results are discussed in terms of a mathematical model for this kind of tumor.
APA, Harvard, Vancouver, ISO, and other styles
8

Pradhan, Asima, C. C. Tang, R. R. Alfano, J. Cleary, R. Prudente, and E. Celmer. "Time-resolved fluorescence kinetics from benign and malignant tumors." In OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1990. http://dx.doi.org/10.1364/oam.1990.tuoo6.

Full text
Abstract:
We have measured fluorescence kinetics from benign tumor tissues and cancerous human breast tissues. The samples were excited with the third-harmonic, 353 nm, 5 ps pulse of a mode-locked Nd glass laser with 30 mJ of energy. We measured the fluorescence lifetimes at different wavelengths using a streak camera with 10 ps resolution. The results display double-exponential fluorescence decay profiles. It appears that the fast component of the decay in the malignant tumors is faster (û ps) than that of the benign tumors (200 ps). The slow component of the decay from malignant tumors was slower (2.4 ns) than that of the benign tumors ( ns). The faster fast component of malignant tumor implies more nonradiative processes. These preliminary results indicate that benign tumors can be distinguished from malignant tumors.
APA, Harvard, Vancouver, ISO, and other styles
9

Savita, Pannu, and Khullar Harsha. "Two interesting cases of granulosa cell tumor: A case report." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685326.

Full text
Abstract:
Introduction: Granulosa cell tumor (GCT) is an ovarian malignancy that arise from granulosa cells of the ovary. This tumour is a type of the sex cord-gonadal stromal tumour. GCT have good prognosis in comparison with other epithelial tumors. Methodology: Two cases of granulosa cell tumors were diagnosed in sir Ganga ram hospital, Rajendernagar, New Delhi in December 2015 and January 2016. The patient’s age, clinical manifestations, radiological and histopathological findings were evaluated. One was in perimenopausal age group and other case was in postmenopausal age group. The clinical manifestations were menorrhagia and abdominal pain. Ultrasonographically, in one case focal hypoechoic zone showing peripheral hypervascularity with possibility of old hemorrhage follicular cyst was seen and in other case of granulosa cell tumors was both solid and cystic areas were seen. Histologically, variety of patterns like diffuse, trabecular, nodular, sheets, nests and fascicular patterns with nuclear grooving in ovarian tissue. In addition endometrial findings were suggestive of simple hyperplasia without atypia. Treatment modalility used was surgery i.e., Total hysterectomy and bilateral salpingo-oophorectomy in both cases. Conclusion: Granulosa cell tumor of the ovary is a rare ovarian malignancy. Endometrial pathology to rule out endometrial carcinomaspecially when postmenopausal bleeding is concomitant finding is advised. Radical surgery is usually not required.
APA, Harvard, Vancouver, ISO, and other styles
10

Savita, Pannu, and Khullar Harsha. "Two interesting cases of granulosa cell tumor: A case report." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685309.

Full text
Abstract:
Introduction: Granulosa cell tumor (GCT) is an ovarian malignancy that arise from granulosa cells of the ovary. This tumour is a type of the sex cord-gonadal stromal tumour. GCT have good prognosis in comparison with other epithelial tumors. Methodology: Two cases of granulosa cell tumors were diagnosed in sir Ganga ram hospital, Rajender Nagar, New Delhi in December 2015 and January 2016. The patient’s age, clinical manifestations, radiological and histopathological findings were evaluated. One was in perimenopausal age group and other case was in postmenopausal age group. The clinical manifestations were menorrhagia and abdominal pain. Ultrasonographically, in one case focal hypoechoic zone showing peripheral hypervascularity with possibility of old hemorrhage follicular cyst was seen and in other case of granulosa cell tumors was both solid and cystic areas were seen. Histologically, variety of patterns like diffuse, trabecular, nodular, sheets, nests and fascicular patterns with nuclear grooving in ovarian tissue. In addition endometrial findings were suggestive of simple hyperplasia without atypia. Treatment modalility used was surgery i.e. Total hysterectomy and bilateral salpingo-oophorectomy in both cases. Conclusion: Granulosa cell tumor of the ovary is a rare ovarian malignancy. Endometrial pathology to rule out endometrial carcinoma specially when postmenopausal bleeding is concomitant finding is advised. Radical surgery is usually not required.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumors"

1

Condeelis, John. Isolation of Motile Tumor Cells From Live Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, June 2001. http://dx.doi.org/10.21236/ada395259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Condeelis, John. Isolation of Motile Tumor Cells from Live Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada412991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sharma, Ashish, Chugh D K, Samarth Agarwal, Nripesh Sadasukhi, H. L. Gupta, Manish Gupta, T. C. Sadasukhi, et al. Bladder Perforation During Trans-Urethral Resection of Bladder Tumors: Is the Open Exploration Ever Indicated? International Journal of Surgery, March 2024. http://dx.doi.org/10.60122/j.ijs.2024.10.05.

Full text
Abstract:
Objectives: Management of bladder perforation during TURBT and to evaluate the need for open exploration? Materials and Methods: A retrospective study design was done and 1550 patients underwent TURBT for bladder mass from January 2005 to November 2023. 52 patients were identified with bladder perforation. 20 patients with T2 tumour on biopsy were excluded from final analysis. Parameters recorded on occurrence of a perforation included patient age and sex, tumor stage, grade, multiplicity, size, location, type of bladder perforation and management undertaken. Results: Of a total of 32 patients, 20 were male and 12 patients were female. The mean age of presentation was 65±12.34yrs. 19 patients had T1 tumors. The site of urinary bladder associated with the highest perforation was postero-lateral wall seen in 14 patients. None of the patients had past history of TURBT or were previously operated. A total of 10 patients (31.25%) had intra-peritoneal perforation and 22 patients (68.75%) had extra-peritoneal perforation. Conclusion: We conclude from our study that open exploration is seldom required for bladder perforation during TURBT unless there are signs of peritonism.
APA, Harvard, Vancouver, ISO, and other styles
4

Baldwin, Albert S. Promotion of Tumor-Initiating Cells in Primary and Recurrent Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada613713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Baldwin, Albert S. Promotion of Tumor-Initiating Cells in Primary and Recurrent Breast Tumors. Fort Belvoir, VA: Defense Technical Information Center, July 2013. http://dx.doi.org/10.21236/ada596410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kennel, S. (Biological markers for tumors). Office of Scientific and Technical Information (OSTI), January 1989. http://dx.doi.org/10.2172/5469723.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Prestwich, Glenn D. Targeted Chemotherapy of Tumors and Metastases With Hyaluronic Acid-Anti-Tumor Bioconjugates. Fort Belvoir, VA: Defense Technical Information Center, August 2001. http://dx.doi.org/10.21236/ada398191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Prestwich, Glenn D. Targeted Chemotherapy of Tumors and Metastases With Hyaluronic Acid-Anti-Tumor Bioconjugates. Fort Belvoir, VA: Defense Technical Information Center, August 1999. http://dx.doi.org/10.21236/ada383364.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Estevez-Ordonez, Dagoberto, Matthew Jarrell, Travis Atchley, Nick Laskay, Mark Hadley, and Mohommad Hamo. Systematic Review of Spinal Glial Tumors. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2023. http://dx.doi.org/10.37766/inplasy2023.4.0085.

Full text
Abstract:
Review question / Objective: Does the extent of resection of intramedullary spinal cord astrocytomas affect oncologic and neurologic outcomes? Condition being studied: Intramedullary spinal cord tumors, which are a class of tumors arising from the cells from within the spinal cord. Study designs to be included: Randomized clinical trials, clinical and observational studies, and case series with available abstracts and published as full-scale original articles, brief reports in peer-reviewed academic journals or descriptive publications on surgical techniques with no restriction on language or time of publication.
APA, Harvard, Vancouver, ISO, and other styles
10

Swafford, D. S., J. Tesfaigzi, and S. A. Belinsky. Expression of the p16{sup INK4a} tumor suppressor gene in rodent lung tumors. Office of Scientific and Technical Information (OSTI), December 1995. http://dx.doi.org/10.2172/381388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumors' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography